middle.news

CLINUVEL Unveils Promising Vitiligo Repigmentation Cases with SCENESSE®

8:35am on Friday 19th of September, 2025 AEST Healthcare
Read Story

CLINUVEL Unveils Promising Vitiligo Repigmentation Cases with SCENESSE®

8:35am on Friday 19th of September, 2025 AEST
Key Points
  • Three vitiligo patients showed notable repigmentation after SCENESSE® treatment
  • Treatment combined seven SCENESSE® implants with up to 40 NB-UVB phototherapy sessions
  • Patients reported satisfaction and no unexpected safety issues
  • Repigmentation effects remained stable 14 weeks post-treatment
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Clinuvel Pharmaceuticals (ASX:CUV)
OPEN ARTICLE